A narrative review of the neuropharmacology of synthetic cathinones—Popular alternatives to classical drugs of abuse

Abstract

Objective To review the literature on the neuropharmacology of synthetic cathinones. Methods A comprehensive literature search was carried out across multiple databases (mainly PubMed, World Wide Web, and Google Scholar) using relevant keywords. Results Cathinones exhibit a broad toxicological profile, mimicking the effects of a wide variety of ‘classic drugs’ such as 3,4‐methylenedioxymethamphetamine (MDMA), methamphetamine and cocaine. Even small structural changes affect their interactions with key proteins. This article reviews existing knowledge of the mechanisms of action of cathinones at the molecular level, and key findings from research on their structure‐activity relationship. The cathinones are also classified according to their chemical structure and neuropharmacological profiles. Conclusions Synthetic cathinones represent one of the most numerous and widespread groups among new psychoactive substances. Initially developed for therapeutic purposes, they quickly started to be used recreationally. With a rapidly increasing number of new agents entering the market, structure‐activity relationship studies are valuable for assessing and predicting the addictive potential and toxicity of new and potential future substances. The neuropharmacological properties of synthetic cathinones are still not fully understood. A full elucidation of the role of some key proteins, including organic cation transporters, requires detailed studies.

Experience and views of healthcare professionals towards people who use new psychoactive substances: Evidence from statutory, non‐statutory, and private mental health and addiction healthcare services

“…The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2022) informs evidence‐based research on the different NPS types which are cathinones, synthetic cannabinoid antagonist receptors (SCRAs), Synthetic Opioid Agonists, stimulants, dissociative, empathogens, depressants, and psychedelics. In addition, some empathogen‐related NPSs have MDMA‐type effects related to the phenethylamine family‐ chemical compounds related to ecstasy (Corkery & Schifano, 2022; Guirguis et al., 2017; Kuropka et al., 2023). In the United Kingdom, HCPs across HCSs and policymakers remain under‐informed about the most appropriate response towards PWUNPS.…”